Pembrolizumab-Induced Pancreatic Exocrine Insufficiency Complicated by Severe Hepatic Steatosis.

Hong, Alex S; Sarwar, Naveed; Goldin, Robert D; Dhar, Ameet; Possamai, Lucia A

Hong, Alex S; Sarwar, Naveed; Goldin, Robert D; Dhar, Ameet; Possamai, Lucia A.

Afiliación

Hong AS; Gastroenterology and Hepatology, Imperial College School of Medicine, London, GBR.
Sarwar N; Medical Oncology, Department of Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, GBR.
Goldin RD; Section for Pathology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, GBR.
Dhar A; Gastroenterology and Hepatology, Department of Hepatology, Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, GBR.
Possamai LA; Gastroenterology and Hepatology, Department of Hepatology, Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, GBR.

Cureus ; 14(7): e26596, 2022 Jul.

Article en En | MEDLINE | ID: mdl-35936135

Palabras clave

hepatic steatosis; immune-related adverse event; immunotherapy; pancreatic exocrine insufficiency; pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cureus Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cureus Año: 2022 Tipo del documento: Article